Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Proto Axiom, a Sydney Biomedical Incubator, Raises $20 Million

publication date: Aug 14, 2024

Proto Axiom, an Australian biomedical incubator, announced a $20 million first close of a Series B round that is expected to raise $30 million eventually. Proto Axiom describes itself as a holistic enterprise that offers technical oversight, administrative support, future financing and hands-on research assistance. Its aims to develop Australian biopharma technology from its Sydney base. With the first closing of the Series B and the $15 million Series A, Proto Axiom has a valuation of $90 million. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here